Daniel Pearlstein
Daniel Pearlstein is an equity research analyst with M Partners covering the Life Sciences sector. His previous experience includes analyst roles at a North American healthcare venture capital firm, a medical device startup and a technology transfer incubator. Pearlstein holds a bachelor's degree in chemistry and a master's degree in management.
Recent Quotes
"CYNA finished Q2/15 with over $111M in cash; it is well capitalized."
—
Daniel Pearlstein, M Partners
(8/19/15)
more >
"Early data on BCT's BriaVax is encouraging, which should drive the stock to appreciate."
—
Daniel Pearlstein, M Partners
(7/23/15)
more >
"CYNA closed its U.S. offering on June 23, raising $72.5M."
—
Daniel Pearlstein, M Partners
(7/7/15)
more >
"The definitive agreement sets up BCT to prepare enough samples for use in Phase 1/2 trials in Q4/15."
—
Daniel Pearlstein, M Partners
(6/17/15)
more >
"We continue to like CTH as a play in the Parkinson's space."
—
Daniel Pearlstein, M Partners
(5/27/15)
more >
"Yesterday, CTH announced a $21M private placement at $0.95."
—
Daniel Pearlstein, M Partners
(4/1/15)
more >
"CTH intends to submit a 505(b)(2) NDA to the FDA in mid-late 2016."
—
Daniel Pearlstein, M Partners
(3/12/15)
more >
"The vote of confidence CTH has received from The Michael J. Fox Foundation is very advantageous."
—
The Life Sciences Report Interview with Daniel Pearlstein
(1/8/15)
more >
